# Disc Medicine, Inc.: overview

IRON · Nasdaq · CIK 1816736 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/iron.md) · [Financials](/companies/iron/financials.md) · [Filings](/companies/iron/filings.md) · [Insiders](/companies/iron/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.89)](/filings/0001193125-25-268200.md) | not reported | [(1.02)](/filings/0001193125-26-205192.md) | [(1.58)](/filings/0001193125-26-325034.md) | [(1.77)](/filings/0001193125-25-268200.md) | not reported | [(1.65)](/filings/0001193125-26-205192.md) | [(1.54)](/filings/0001193125-26-325034.md) |
| Free cash flow | $m | [(17.4) d](/filings/0001193125-25-268200.md) | [(28.0) d](/filings/0001193125-26-073602.md) | [(42.2)](/filings/0001193125-26-205192.md) | [(48.0) d](/filings/0001193125-26-325034.md) | [(47.8) d](/filings/0001193125-25-268200.md) | [(43.3) d](/filings/0001193125-26-073602.md) | [(62.2)](/filings/0001193125-26-205192.md) | [(44.2) d](/filings/0001193125-26-325034.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(40.95)](/filings/0000950170-23-011139.md) | [(45.05)](/filings/0000950170-24-034432.md) | [(3.42)](/filings/0001193125-26-073602.md) | [(3.96)](/filings/0001193125-26-073602.md) | [(6.01)](/filings/0001193125-26-073602.md) |
| Free cash flow | $m | [(27.6)](/filings/0000950170-23-011139.md) | [(42.4)](/filings/0000950170-24-034432.md) | [(73.6)](/filings/0001193125-26-073602.md) | [(94.4)](/filings/0001193125-26-073602.md) | [(181)](/filings/0001193125-26-073602.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/iron/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $358.0m | 4,894,473 |  | Reduced −692,421 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $180.5m | 2,467,899 |  | Added +194,068 |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $179.2m | 2,450,221 |  | Unchanged |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $139.9m | 1,875,795 |  | Added +504,315 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $127.4m | 1,741,351 |  | Added +5,975 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $120.6m | 1,648,836 |  | Reduced −49,408 |
| [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $113.4m | 1,550,000 |  | Added +850,000 |
| [Atlas Venture Life Science Advisors, LLC](/funds/1917529.md) | 2026-06-30 | $110.7m | 1,513,875 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $100.1m | 1,369,027 |  | Reduced −6,403 |
| [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $99.1m | 1,354,852 |  | Unchanged |

## Recent filings

[All 771 filings](/companies/iron/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-26 | 17:52 ET | [SCHEDULE 13D/A](/filings/0001193125-26-432228.md) | Ownership report, active investor, amended | 0001193125-26-432228 |
| 2026-10-22 | 17:11 ET | [8-K](/filings/0001193125-26-429105.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-429105 |
| 2026-10-19 | 07:08 ET | [8-K](/filings/0001193125-26-424649.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-424649 |
| 2026-09-10 | 08:48 ET | [8-K](/filings/0001193125-26-387351.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-387351 |
| 2026-07-30 | 08:34 ET | [10-Q](/filings/0001193125-26-325034.md) | Quarterly report, period 2026-06-30 | 0001193125-26-325034 |
| 2026-07-30 | 08:32 ET | [8-K](/filings/0001193125-26-325031.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-325031 |
| 2026-06-30 | 16:16 ET | [8-K](/filings/0001193125-26-290542.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001193125-26-290542 |
| 2026-06-24 | 16:22 ET | [8-K](/filings/0001193125-26-281096.md) | 5.07 Shareholder vote results | 0001193125-26-281096 |
| 2026-05-05 | 08:33 ET | [10-Q](/filings/0001193125-26-205192.md) | Quarterly report, period 2026-03-31 | 0001193125-26-205192 |
| 2026-05-05 | 08:32 ET | [8-K](/filings/0001193125-26-205187.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-205187 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-073602.md), filed Feb 26, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1816736
- Tickers: IRON
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 17:53 ET. No prices; not investment advice.